Genmark Diagnostics Inc. (NASDAQ:GNMK): Eli Casdin’s Casdin Capital filed an amended 13D.
You can check out Casdin Capital’s latest holdings and filings here.
Please follow Casdin Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Casdin Capital or update its stock holdings.
Follow Eli Casdin's Casdin Capital
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Casdin Capital | 0 | 3,850,000 | 0 | 3,850,000 | 3,850,000 | 7.0% |
Casdin Partners Master Fund | 0 | 3,850,000 | 0 | 3,850,000 | 3,850,000 | 7.0% |
Casdin Partners GP | 0 | 3,850,000 | 0 | 3,850,000 | 3,850,000 | 7.0% |
Eli Casdin | 0 | 3,850,000 | 0 | 3,850,000 | 3,850,000 | 7.0% |
Follow Eli Casdin's Casdin Capital
Page 1 of 11 – SEC Filing
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
13D
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.)*
GenMark Diagnostics, Inc. |
(Name of Issuer) |
Common Stock, $0.0001 par value |
(Title of Class of Securities) |
372309104 |
(CUSIP Number) |
Eli Casdin Casdin Capital, LLC 1350 Avenue of the Americas, Suite 2405 New York, New York Telephone Number (212) 897-5438 |
(Name, Address and Telephone Number of Person Notices and Communications) |
March 20, 2018 |
(Date of Event Which Requires Filing of this Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [_]. | |
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 2 of 11 – SEC Filing
CUSIP No. | 372309104 |
1. | NAME OF REPORTING PERSONS | |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
Casdin Capital, LLC |
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [_] |
(b) [_] | ||
3. | SEC USE ONLY | |
4. | SOURCE OF FUNDS | |
AF |
5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | [_] |
6. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON |
7. | SOLE VOTING POWER | |
0 |
8. | SHARED VOTING POWER | |
3,850,000 |
9. | SOLE DISPOSITIVE POWER | |
0 |
10. | SHARED DISPOSITIVE POWER | |
3,850,000 |
11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
3,850,000 |
12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | [_] |
13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |
7.0% |
14. | TYPE OF REPORTING PERSON | |
IA | ||
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 3 of 11 – SEC Filing
CUSIP No. | 372309104 |
1. | NAME OF REPORTING PERSONS | |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
Casdin Partners Master Fund, L.P. |
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [_] |
(b) [_] | ||
3. | SEC USE ONLY | |
4. | SOURCE OF FUNDS | |
WC |
5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | [_] |
6. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
Cayman Islands |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON |
7. | SOLE VOTING POWER | |
0 |
8. | SHARED VOTING POWER | |
3,850,000 |
9. | SOLE DISPOSITIVE POWER | |
0 |
10. | SHARED DISPOSITIVE POWER | |
3,850,000 |
11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
3,850,000 |
12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | [_] |
13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |
7.0% |
14. | TYPE OF REPORTING PERSON | |
PN | ||
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 4 of 11 – SEC Filing
CUSIP No. | 372309104 |
1. | NAME OF REPORTING PERSONS | |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
Casdin Partners GP, LLC |
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [_] |
(b) [_] |
3. | SEC USE ONLY | |
4. | SOURCE OF FUNDS | |
AF |
5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | [_] |
6. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON |
7. | SOLE VOTING POWER | |
0 |
8. | SHARED VOTING POWER | |
3,850,000 |
9. | SOLE DISPOSITIVE POWER | |
0 |
10. | SHARED DISPOSITIVE POWER | |
3,850,000 |
11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
3,850,000 |
12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | [_] |
13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |
7.0% |
14. | TYPE OF REPORTING PERSON | |
OO | ||
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 5 of 11 – SEC Filing
CUSIP No. | 372309104 |
1. | NAME OF REPORTING PERSONS | |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | ||
Eli Casdin |
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [_] |
(b) [_] |
3. | SEC USE ONLY | |
4. | SOURCE OF FUNDS | |
AF |
5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) | [_] |
6. | CITIZENSHIP OR PLACE OF ORGANIZATION | |
United States of America |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON |
7. | SOLE VOTING POWER | |
0 |
8. | SHARED VOTING POWER | |
3,850,000 |
9. | SOLE DISPOSITIVE POWER | |
0 |
10. | SHARED DISPOSITIVE POWER | |
3,850,000 |
11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
3,850,000 |
12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | [_] |
13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |
7.0% |
14. | TYPE OF REPORTING PERSON | |
IN | ||
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 6 of 11 – SEC Filing
CUSIP No. | 372309104 |
Item 1. | Security and Issuer. |
The name of the issuer is GenMark Diagnostics, Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s principal executive offices is 5964 La Place Court, Carlsbad, California 92008-8829. This Schedule 13D relates to the Issuer’s Common Stock, $0.0001 par value (the “Shares”). | ||
Item 2. | Identity and Background. |
(a), (f) | This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company (“Casdin”), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the “Fund”), Casdin Partners GP, LLC, a Delaware limited liability company (the “GP”) and Eli Casdin, a United States citizen (collectively, the “Reporting Persons”). | ||
(b) | The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2405, New York, New York 10019. | ||
(c) | Eli Casdin is the managing member of Casdin and the GP. The principal business of Casdin is serving as an investment adviser to its clients. The principal business of the GP is serving as the general partner to certain private funds. Casdin is the investment manager to the Fund and the GP is the general partner of the Fund. The principal business of the Fund is purchasing, holding and selling securities for investment purposes. | ||
(d), (e) | During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Persons disclaim membership in a group. | ||
Item 3. | Source and Amount of Funds or Other Consideration. | |
The funds for the purchase of the Shares by the Fund came from the working capital of the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion. No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business. | ||
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 7 of 11 – SEC Filing
Item 4. | Purpose of Transaction. | |
The Reporting Persons have acquired their Shares The Reporting Persons, however, reserve the The Reporting Persons have been and may continue The Reporting Persons further reserve the right | ||
Item 5. | Interest in Securities of the Issuer. | ||
(a) – (e) | As of the date hereof, the Reporting Persons Casdin has the sole power to vote or direct The Fund has the sole power to vote or direct The GP has the sole power to vote or direct Eli Casdin has the sole power to vote or direct The transactions by the Reporting Persons in *This outstanding Shares figure reflects the | ||
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 8 of 11 – SEC Filing
Item 6. | Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. | |
Not Applicable | ||
Item 7. | Material to be Filed as Exhibits. |
Exhibit A: Joint Filing Agreement Exhibit B: Schedule of Transactions in Shares | ||
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 9 of 11 – SEC Filing
SIGNATURE
After reasonable inquiry and to the best of
my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
March 27, 2018 | ||
(Date) |
Casdin Capital, LLC* By: /s/ Eli Casdin | |
(Signature) | |
Eli Casdin, Managing Member | |
(Name/Title) |
Casdin Partners Master Fund, L.P. By: Casdin Partners GP, LLC, its general partner By: /s/ Eli Casdin | |
(Signature) | |
Eli Casdin, Managing Member | |
(Name/Title) |
Casdin Partners GP, LLC* By: /s/ Eli Casdin | |
(Signature) | |
Eli Casdin, Managing Member | |
(Name/Title) | |
/s/ Eli Casdin* | |
Eli Casdin |
* This reporting person disclaims beneficial
ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed
an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities
Exchange Act of 1934, as amended, or for any other purpose.
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (see 18 U.S.C. 1001).
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 10 of 11 – SEC Filing
Exhibit A
AGREEMENT
The undersigned agree that
this Schedule 13D, dated March 27, 2018, relating to the Common Stock, $0.0001 par value of GenMark Diagnostics, Inc. shall be
filed on behalf of the undersigned.
March 27, 2018 | ||
(Date) |
Casdin Capital, LLC By: /s/ Eli Casdin | |
(Signature) | |
Eli Casdin, Managing Member | |
(Name/Title) |
Casdin Partners Master Fund, L.P. By: Casdin Partners GP, LLC, its general partner By: /s/ Eli Casdin | |
(Signature) | |
Eli Casdin, Managing Member | |
(Name/Title) |
Casdin Partners GP, LLC By: /s/ Eli Casdin | |
(Signature) | |
Eli Casdin, Managing Member | |
(Name/Title) | |
/s/ Eli Casdin | |
Eli Casdin |
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Follow Genmark Diagnostics Inc. (NASDAQ:GNMK)
Page 11 of 11 – SEC Filing
Exhibit B
Schedule of Transactions in Shares
Date of Transaction | Title of Class | Number of Shares Acquired | Number of Shares Disposed | Price Per Share* |
1/26/2018 | Common Stock, $0.0001 par value | 270,000 | 0 | $5.93 |
2/26/2018 | Common Stock, $0.0001 par value | 195,000 | 0 | $4.57 |
2/27/2018 | Common Stock, $0.0001 par value | 155,000 | 0 | $4.71 |
*The price per share represents the average price for all trading
by the Reporting Persons in the Shares on the relevant date.